The Exciting Rise of ENDEXX CORPORATION COM USD0.001 (OTCMKTS:EDXC)

The Exciting Rise of ENDEXX CORPORATION COM USD0.001 (OTCMKTS:EDXC)

SHARE

ENDEXX CORPORATION COM USD0.001 (OTCMKTS:EDXC) is a low-priced trading equity that has started to engage some focus among traders and investors as prices get a little traction in bounce mode. Motivating the recent rise, the company just confirmed adjusted annual revenue growth at 145%. According to the recent release, the fiscal first quarter continued the trend of 20% quarterly growth. That company notes that growth is being driven by increased demand for both its human and pet products derived from Industrial Hemp extracts formulated with organic and natural food edible delivery systems.

Recent action has seen 65% tacked on to share pricing for the listing in the past month. The situation may be worth watching. EDXC is a stock whose past is littered with sudden rips. What’s more, the company has seen interest climb, with an increase in recent trading volume of a bit over 200% over the long run average.

ENDEXX CORPORATION COM USD0.001 (OTCMKTS:EDXC) frames itself as a company that provides innovative inventory management and technology solutions.

According to company materials, Endexx, with its collaborative partners and consultants, develops and distributes two consumable product lines derived from industrial hemp, which is organic and naturally rich in phytocannabinoids. Phyto-Bites®, is its CBD-infused soft chews for dogs.

The dog treats are formulated to promote health and support the reduction of separation anxiety, pain and inflammation. The company also has two technology products and services that launched in 2014 — the M3hub and the Autospense. Both products provide essential solutions to promote regulatory compliance and full accountability through “seed to sale” inventory management and an “End of Sale” technology integration.

Based on principles developed by the pharmacological industry, the m3hub platform is the first standardized software solution for tracking pharmaceutical grade marijuana that maintains compliance with federal, state and local regulations. It is intended to provide a smooth transition to eventual federal mandates. The Autospense is a commercial grade inventory control and dispensing device that provides up-to-the-minute accounting details and ensures both product and patient security.

“By automating the dispensing process, Autospense increases productivity and reduces costs for marijuana retailers, while enhancing their service quality by reducing transaction time for customers.”

The company was formerly known as Visual Board Books, Inc. and changed its name to ENDEXX Corporation in February 2005. ENDEXX Corporation is headquartered in Cave Creek, Arizona.

Find out when $EDXC stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

In the company’s most recent release, management cites recent forecasts by Forbes Magazine, the growth of the CBD Market is expected to grow 700% to $2.1 billion by 2020.

Todd Davis, CEO of Endexx, stated, “We appreciate Forbes coverage on the tremendous growth opportunity in the CBD market in the United States. In recent years there has been a lot of solid scientific research done to understand the science behind why the non-intoxicating CBD extract from the hemp plant has so many powerful therapeutic uses. We are participating in this forecasted 700% growth in several areas but specifically through our Phyto-Bytes CBD infused soft chews for dogs.”

As the company notes, this growth is being driven by the understanding that all mammals, including humans, have an EndoCannabinoid System within the body that controls the way the body reacts to normal physiological processes. This molecular signaling system controls how the human body experiences pain, stress, hunger, sleep, circadian rhythms, blood pressure, body temperature, bone density, fertility, intestinal fortitude, mood, metabolism, memory retention, and more. The EndoCannabinoid System produces naturally occurring cannabinoids, which stimulates the body’s cannabinoid receptors.

The growth being reported by the company is based on unaudited financial records, and builds on extremely small numbers. For example, in their last reporting period, the company made $67k in total sales. We encourage you to keep this in mind as you evaluate this company.

Now commanding a market cap of $1.8M, EDXC has virtually no cash on the books, which is balanced by about $228K in total current liabilities. One should also note that debt has been growing over recent quarters. The company is apparently seeing top line growth from nominal sales levels according to their own unaudited reports. We will update the story again soon as developments transpire. For continuing coverage on shares of $EDXC stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!

Sign Up for our 100% FREE Oracle Dispatch Newsletter